Critical Challenges in
Acute Coronary Syndromes

The Road from REPLACE-2 to
ACUITY and HORIZONS MI

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This symposium is designed for • Cardiologists, non-invasive specialists • Cardiologists, invasive specialists • Coronary care unit (CCU) specialists and directors • Specialists in invasive vascular management • Program direc tors, cardiovascular medicine • Fellows in cardiovascular medicine • Clinical pharmacists and pharmacologists • Pharmacy directors (cardiovascular medicine) • Investigators and clinical trial specialists, invasive cardiology • Cardiac catheterization healthcare personnel • Interventional radiologists (vascular medicine) • Emergency medicine specialists • Cardiovascular nurses

Registration:

Enrollment for this webcast is complimentary, and clinicians are invited to attend this CME-certified symposium and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from The Medicines Company, Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

E. Magnus Ohman, MD, FRCPI, FACC
Research Grants: Berlex, sanofi-aventis, Schering-Plough Corporation, Bristol Meyer Squibb, and Millennium.
Stockholder: Medtronic. Consultant: Response Biomedical, Liposcience, and Inovise Medical

C. Michael Gibson, MS, MD
Present Research/Grant Funding: CardioKinetix, Eli Lilly, KAI Pharmaceuticals, Nuvelo, Schering Plough Corporation, Sanofi-Aventis, St. Jude Medical, Baxter, Novartis, FoldRx, INO Therapeutics, LLC
Speakers Bureau: Genentech, Inc., GlaxoSmithKline, Schering Plough Corporation, The Medicines Company
Consultant: Angel Medical Systems, The Medicines Company. HeartScape Technologies, Inc., Ascenta Therapeutics, Inc., Archemix Corp., PDL Pharmaceuticals, Atrium Medical Corporation, TIMI3 Systems, Biogen IDEC

Charles V. Pollack Jr, MA, MD, FACEP, FAAEM
Grant/Research Support: GlaxoSmithKline
Consultant: The Medicines Co., Schering-Plough, Sanofi-Aventis, BMS, Genentech
Speaker’s Bureau: Schering-Plough, Sanofi-Aventis, BMS, Genentech

A. Michael Lincoff, MD
Relationships with Industry Research Sponsors
C5Research:
Abraxis, Alexion Pharma, AstraZeneca, Atherogenics, Aventis, Biosense Webster, Biosite,
Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb (BMS), Cardionet, Centocor,
Converge Medical Inc., Cordis, Dr. Reddy’s Laboratory, Novartis, Novo Nordisk, Orphan Therapeutics, P&G Pharma, Pfizer, Roche, Sankyo, Sanofi-Aventis, Schering-Plough, Scios, St. Jude Medical, Takeda, VasoGenix. Viacor

Program Faculty:

Program Chairman
E. Magnus Ohman, MD, FRCPI, FACC
Professor of Medicine
Director, Program for Advanced Coronary Disease
Division of Cardiology
Duke University Medical Center
Durham, North Carolina
Cleveland, Ohio


Distinguished Faculty
C. Michael Gibson, MS, MD
Director, TIMI Core Laboratories and Data Coordinating Center
Associate Professor
Harvard Medical School
Boston, Massachusetts

A. Michael Lincoff, MD
Vice Chairman for Research
Department of Cardiovascular Medicine
Director, Cleveland Clinic Cardiovascular Coordinating Center
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
The Cleveland Clinic Foundation
Cleveland, Ohio

Charles V. Pollack Jr, MA, MD, FACEP, FAAEM
Chairman, Department of Emergency Medicine
Pennsylvania Hospital
Professor of Emergency Medicine
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Educational Objectives:

• Learn to identify signs, symptoms, and prognostic features of acute coro nary syndrome and related ischemic conditions, and their implications for invasive vascular management.
• Learn how recently issued AHA/ACC Guidelines for Non ST-Eleva tion Myocardial Infarction are best applied to appropriately risk-stratified patients with UA and NSTEMI.
• Learn to assess and implement optimal pharmacologic inter ventions, especially antithrombotic therapy in the upstream set ting, for patients presenting with manifestations of UA, NSTEMI, STEMI, and related conditions.
• Learn to understand the implications of recent clinical data, trials, and recommendations on switching antithrombotic therapy in patients who present with acute ischemic coronary syndromes, with an emphasis on determining when switching from one agent to another is appropriate, safe, and feasible, and when switching among antithrombotic agents may be problematic.
• Learn to characterize, identify, and evaluate the safety, efficacy, and side effects of myriad therapeutic options used for acute isch emic coronary syndromes including, aspirin, antiplatelet agents, direct thrombin inhibitors, UFH, LMWHs, and factor Xa inhibitors.
• Learn to understand the specific advantages and potential dis advantages of pharmacologic agents currently used to reduce ischemic and bleeding end points in the setting of cardiovas cular emergencies.
• Learn to identify the ideal properties of antithrombotic agents used in conjunction with stent insertion.
• Learn to discuss and assess the impact that new trials and AHA/ACC Guidelines are likely to have on future invasive man agement of patients with NSTEMI.
• Learn to apply national guidelines and expert, consensus-based recommendations in order to optimize invasive vascular manage ment of patients with acute, ischemic heart disease.

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright (c) 2007 All rights reserved